贤丰控股(002141) - 2024 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2024 was ¥28,559,136.50, a decrease of 35.82% compared to ¥44,500,982.34 in the same period last year[11]. - The net profit attributable to shareholders was ¥5,443,748.22, a significant improvement of 122.98% from a loss of ¥23,690,175.34 in the previous year[11]. - The net cash flow from operating activities was -¥17,972,097.65, showing a 53.07% improvement from -¥38,296,134.46 in the same period last year[11]. - Basic earnings per share increased to ¥0.0048, compared to a loss of ¥0.0209 in the previous year, marking a 122.97% improvement[11]. - The company reported a net profit excluding non-recurring gains and losses of -¥15,403,169.30, an improvement of 58.18% from -¥36,830,313.11 in the previous year[11]. - The company achieved a net profit of 5.44 million yuan in the reporting period, marking a turnaround from losses in the same period last year[15]. - The company reported a net loss for the 2023 fiscal year, with operating revenue below CNY 100 million, which may trigger delisting risk warnings from the Shenzhen Stock Exchange[47]. - The company reported a significant drop in other receivables from CNY 1,567,310.00 to CNY 1,172,830.33, a decrease of approximately 25.1%[81]. - The total comprehensive income for the first half of 2024 was CNY 14,911,857.17, contrasting with a total comprehensive loss of CNY -7,270,773.24 in the first half of 2023[91]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,077,653,453.40, a decrease of 9.64% from ¥1,192,593,505.11 at the end of the previous year[11]. - Net assets attributable to shareholders decreased to ¥936,244,804.78, down 9.20% from ¥1,031,077,872.65 at the end of the previous year[11]. - The company's cash and cash equivalents decreased to ¥53,745,405.70, representing 4.99% of total assets, down from 12.28%, a decrease of 7.29% due to share buybacks[22]. - Total liabilities decreased from CNY 100,871,146.43 to CNY 80,554,308.47, a reduction of about 20.2%[83]. - The company's equity attributable to shareholders decreased from CNY 1,031,077,872.65 to CNY 936,244,804.78, a decline of approximately 9.2%[83]. - The total equity of the company was CNY 633,691,981.08, down from CNY 718,782,568.84, indicating a decline of 11.8%[87]. - The total liabilities and owner's equity at the end of the period stand at 1,202,758,097.20 CNY[102]. Operational Challenges - The company faced increased operational pressure due to fierce price competition and collection risks in the veterinary medicine industry, leading to a decline in sales[15]. - The company faced a significant adjustment in recognizing main business income, with an improper recognition of ¥8,848,213.69 in the previous year[11]. - The company is actively pursuing strategic measures to stabilize market confidence, including stock buybacks and operational improvements[15]. - The company is facing significant market competition in its veterinary vaccine business, leading to increased operational pressure[32]. Research and Development - The main business focus is on veterinary vaccines, with six core products for pigs, including vaccines for blue ear disease and porcine reproductive and respiratory syndrome[15]. - The research and development capabilities are supported by a national-level research center and various advanced platforms for vaccine development[16]. - Research and development expenses decreased by 20.74% to ¥5,832,898.92 from ¥7,359,049.64[18]. Shareholder Actions - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[2]. - The stock has been under "delisting risk warning" since April 29, 2024, prompting the company to implement corrective measures to improve its operational status[15]. - The company implemented a share repurchase plan using self-owned funds of CNY 99.9874 million, repurchasing a total of 101,720,721 shares to be canceled and reduce registered capital[42]. - The company repurchased a total of 101,720,721 shares, accounting for 8.96% of the total share capital, with a total transaction amount of approximately RMB 99.99 million[70]. Environmental Compliance - The company has obtained environmental permits, including a wastewater discharge permit valid until July 4, 2027[38]. - The company has established an emergency response plan for environmental incidents, with a registration number valid until July 2025[39]. - The company has a wastewater treatment facility with a capacity of 700 m³/d, ensuring compliance with discharge standards[39]. - The company has no administrative penalties related to environmental issues during the reporting period[40]. Taxation and Financial Planning - The corporate income tax rates for various subsidiaries range from 15% to 25%, with specific entities like Chengdu Shiji at 15% and others at 20%[197][198]. - The company benefits from tax policies supporting small and micro enterprises, allowing a reduced taxable income calculation and a 20% corporate income tax rate until December 31, 2027[200]. - The company has implemented tax planning strategies to estimate the timing and amount of future taxable profits for recognizing deferred tax assets[195]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring the financial statements reflect a true and complete picture of its financial status[111]. - The company has established specific accounting policies for revenue recognition based on its operational characteristics[110]. - The company recognizes revenue when control of the goods is transferred to the customer, ensuring that all contract conditions are met[174]. - The company assesses goodwill impairment annually, estimating future cash flows from asset groups and selecting appropriate discount rates[194].